Background Five major first-and second-generation epidermal growth factor receptor-
tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, icotinib, afatinib, and …

Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …

Aim: To update overall survival (OS) results from a previous network meta analysis
comparing the relative clinical efficacy of epidermal growth factor receptor-targeted tyrosine …

Here, we compare the relative clinical efficacy of EGFR-targeted tyrosine kinase inhibitors
(EGFR TKIs) for EGFR-positive advanced non-small-cell lung cancer (NSCLC). The authors …

Background: To answer which epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) is the best choice for advanced non-small cell lung cancer (NSCLC) EGFR …

Purpose Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
were firmly established as front-line treatment for non–small cell lung cancer (NSCLC) that …

Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for
patients with EGFR mutation-positive (EGFR m+) advanced non-small-cell lung cancer …

Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR
mutations, the suggested course of action is epidermal growth factor receptor-tyrosine …

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
the preferred first-line treatment for nonsmall-cell lung cancer (NSCLC) patients with an …